Acasti Pharma Inc. announced the appointment of Prashant Kohli as Acasti's new Chief Executive Officer, succeeding Jan D'Alvise. The parties have mutually agreed to part ways, and Ms. D'Alvise will be stepping down from the board. Prashant Kohli has served as Chief Commercial Officer of Acasti since 2022.

Mr. Kohli has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Recently, Mr. Kohli was VP, Commercial Operations of Acasti and at Grace Therapeutics, prior to its acquisition by Acasti in August 2021. Mr. Kohli has developed a broad network of KOL physicians who treat Subarachnoid Hemorrhage (SAH) at leading comprehensive stroke centers across the country; Acasti's late-stage clinical program, GTX-104, is for the treatment of SAH.

Mr. Kohli has also held a variety of commercial, corporate, and business development roles at Archi-Tech Systems, Cardinal Health, IQVIA, Rosenbluth, and Dun Bradstreet. He has a BA in Computer Science and Math, and an MBA from The Wharton School. Over his career, Mr. Kohli has built, deployed, and led sales and marketing efforts from the ground-up with significant experience in PL accountability, product development, salesforce design and deployment, branding, market access, and distribution.

He has successfully implemented evidence-based, consultative-selling model that are rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers.